Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $244.5252W HIGH $371.00
Volume
773.38 K
Value Traded
172.33 M
Short % Float
3.17%
Days to Cover
4.2
+9.86%Week
+17.29%1 Month
+16.88%3 Month
+41.26%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
29.31 B
EPS (TTM)
12.36
P/E Ratio
29.24
Ent. Value
35.03 B
Total Shares
81.13 M
Float Shares
80.77 M
Insiders
0.40%
Institutions
101.29%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LH Catalyst Timeline
Dated clinical, regulatory and corporate events for Labcorp Holdings Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Labcorp Holdings Inc.
275Total events
4Upcoming
78Tier-1 (high impact)
2018 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
Waters and Labcorp announce partnership to expand access to BD Onclarity HPV Assay
cervical cancer screening / HPV testingsource ↗
▲Partnership / LicenseCorporate
Charles River, Labcorp and FDA collaborate to develop preclinical abuse-potential screening tools
▲AcquiredCorporate
Labcorp enters agreement to acquire select assets of BioReference Health from OPKO Health for $722M cash plus up to $150M earnout
▲Partnership / LicenseCorporate
Labcorp collaboration with Arianna Huffington's Thrive Global
cardiometabolic healthsource ↗
▲Product LaunchPost-Market
Launch of Thrive 5 Health Test via Labcorp OnDemand in collaboration with Thrive Global
▲Product LaunchpTau-217Post-Market
Launch of FDA-cleared Elecsys pTau-217 blood test for Alzheimer's disease
Alzheimer's diseasesource ↗
▲Partnership / LicenseCorporate
Collaboration with Waters Corporation to offer BD Onclarity™ HPV assay
▲FDA ApprovalFDA Decision
FDA approval of PGDx elio tissue complete CDx as companion diagnostic
advanced melanomasource ↗
▲Product LaunchPost-Market
Labcorp launches FDA-approved VENTANA PTEN (SP218) RxDx Assay nationwide
prostate adenocarcinomasource ↗
▲Quarterly UpdateCorporate
Labcorp raises full-year 2026 revenue growth and adjusted EPS guidance
▲Product LaunchPost-Market
Labcorp launches Marker by Labcorp genetic health panel
genetic healthsource ↗
▲Product LaunchColoSensePost-Market
Labcorp launches ColoSense nationwide for colorectal cancer screening
colorectal cancer screeningsource ↗
▲Partnership / LicenseCorporate
Labcorp enters clinical trial collaboration with Fox Chase Cancer Center for Plasma Detect Genome MRD
non-small cell lung cancersource ↗
▲Product LaunchPost-Market
Labcorp expands nationwide access to Roche's VENTANA PTEN companion diagnostic
Prostate cancersource ↗
▲AcquisitionCorporate
Labcorp completes acquisition of select outreach laboratory services from Parkview Health
▲Partnership / LicenseCorporate
Labcorp expands collaboration with Epic to place 6,500+ diagnostic tests on Aura platform
▲Product LaunchPost-Market
Labcorp introduces Canada's first at-home self-collection test for fertility hormones and testosterone
fertility and testosteronesource ↗
▲Product LaunchPost-Market
Labcorp adds advanced DPYD genotyping test
Chemotherapy toxicity risksource ↗
▲Partnership / LicenseCorporate
Labcorp expands nationwide access to Roche's VENTANA PTEN (SP218) companion diagnostic
prostate cancersource ↗
▲Product LaunchPost-Market
Launch of Marker by Labcorp Genetic Health Panel
hereditary cancer, cardiovascular conditions, metabolic conditionssource ↗
▲Product LaunchPost-Market
Labcorp launches Marker by Labcorp Genetic Health Panel
hereditary cancer, cardiovascular conditions and metabolic conditionssource ↗
▲FDA ApprovalFDA Decision
FDA approval of PGDx elio tissue complete CDx as companion diagnostic for advanced melanoma
advanced melanomasource ↗
▲Partnership / LicenseCorporate
Collaboration with Knight Cancer Institute at OHSU on clinical study of Plasma Detect® Genome MRD Ultra
muscle-invasive bladder cancersource ↗
▲Product LaunchPost-Market
Launch of Advanced Health Panel and Marker by Labcorp™ Genetic Health Panel on Labcorp OnDemand
▲Quarterly UpdateCorporate
Labcorp reports Q2 2026 revenue of $3.73B and diluted EPS of $3.64
▲Product LaunchColoSensePost-Market
Nationwide availability of ColoSense
colorectal cancer screeningsource ↗
▲Product LaunchNASHnextPost-Market
NASHnext launched on Labcorp OnDemand platform
MASH (Metabolic dysfunction-Associated SteatoHepatitis)source ↗
◆Oral PresentationPresentation
Labcorp presentation at Jefferies Global Healthcare Conference
◆Platform ValidationPreclinical
Platform initial validation phase completion
Alzheimer's diseasesource ↗
▲Other Regulator MilestoneColoSenseEx-US Regulatory
CMS National Coverage Determination update covering ColoSense
colorectal cancer screeningsource ↗
●Trial InitiationTrial
Multi-institution trial initiated to evaluate germline genetic testing approaches in colorectal cancer
colorectal cancersource ↗
▲Partnership / LicenseCorporate
Nationwide strategic collaboration with Children's Hospital of Philadelphia (CHOP)
▲Product LaunchPost-Market
Launched Labcorp Fentanyl Visual Urine Test, FDA cleared rapid screening test
fentanyl exposuresource ↗
▲Product LaunchPost-Market
Nationwide availability of PD-L1 IHC 22C3 pharmDx by Labcorp
platinum-resistant ovarian cancersource ↗
▲Partnership / LicenseCorporate
Labcorp and CHOP announce collaboration to accelerate pediatric diagnostics
pediatric diagnosticssource ↗
▲Partnership / LicenseCorporate
Labcorp expands collaboration with PathAI to deploy AISight Dx nationwide
▲Product LaunchpTau-181Post-Market
Nationwide launch of Elecsys pTau-181 test in primary care
Alzheimer's diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How LH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Labcorp Holdings Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every LH program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| ANDERSON KERRII BDirector | Sell | -3,000 6,563 held | $318.02 | 08/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PROSIGHT MANAGEMENT, LP | 1.8 % | 8.66 M | 34.53 K |
LH Institutional Ownership Trends
LH Short Interest
Shares sold short, counted twice a month.
3.17%
Short % of Float
of tradable shares sold short
2.6M
Shares Sold Short
-4.7% vs prior count
4.2 Moderate
Days to Cover
trading days of normal volume to buy every short share back
606.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LH ranks across every disease it competes in
Competitive Position is a premium feature
See how LH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLH News
-LH
Oct 28, 2026▲ +8.8%on this news
Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
Labcorp reported strong third-quarter results for 2026, with revenues of $3.81 billion, a 6.9% increase from the previous year. Adjusted EPS rose by 14.5%, prompting the company to raise its full-year guidance. The firm also announced FDA approval for a new diagnostic test for advanced melanoma and advanced its M&A strategy with four transactions.
Read more →-LH
Oct 23, 2026Labcorp Announces Definitive Agreement to Acquire Millennium Health
Labcorp agreed to acquire Millennium Health to expand toxicology testing access nationwide. The deal combines Labcorp’s scale with Millennium’s specialized drug surveillance tools. This integration aims to support patients with chronic pain and substance use disorders. Financial terms remain undisclosed pending regulatory approval.
Read more →-LH
Oct 23, 2026Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
Labcorp and Waters Corporation announced a partnership to provide the FDA-approved BD Onclarity HPV Assay starting in late 2026. This initiative aims to enhance cervical cancer screening access across the U.S. by offering both clinician-collected and self-collected testing options. The assay is the first to support all ASCCP Enduring Risk-Based Management Guidelines.
Read more →-LH
Oct 22, 2026Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
Charles River, in partnership with the FDA and Labcorp, is developing new screening tools to assess the abuse potential of new drugs. This collaboration aims to enhance safety evaluations in drug development. The initiative focuses on quantifying and ranking the abuse potential, which is crucial for regulatory compliance.
Read more →-LH
Oct 22, 2026Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential
Labcorp, the FDA, and Charles River Laboratories announced a collaboration to enhance the evaluation of drug abuse potential. This partnership aims to improve safety in drug development and regulatory decisions by utilizing harmonized behavioral economics methodologies. The initiative seeks to better predict real-world use patterns and protect public health.
Read more →-LH
Oct 21, 2026Labcorp Declares Quarterly Dividend
Labcorp Holdings Inc. announced a quarterly cash dividend of $0.72 per share, payable on December 11, 2026. Stockholders of record as of November 24, 2026, will receive this dividend. The company continues to lead in laboratory services, supporting a significant portion of new FDA drug approvals.
Read more →-LH
Oct 15, 2026Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
Labcorp has announced an agreement to acquire select assets of BioReference Health from OPKO Health for $722 million. This acquisition aims to enhance Labcorp's clinical and women's health testing services and increase access to the proprietary 4Kscore Test, which predicts aggressive prostate cancer. The deal is expected to provide significant revenue growth and improve patient care through expanded diagnostic services. The transaction is subject to regulatory approvals.
Read more →-LH
Oct 13, 2026Labcorp and Arianna Huffington's Thrive Global Collaborate to Launch Thrive 5 Health Test
Labcorp has launched the Thrive 5 Health Test in partnership with Thrive Global, marking the first lab test that integrates health insights with behavior change strategies. This test evaluates five key cardiometabolic health indicators and provides consumers with educational content and actionable steps to improve their health. The initiative aims to empower individuals to take proactive steps towards better health management.
Read more →-LH
Sep 30, 2026Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026
Labcorp Holdings Inc. will announce its financial results for Q3 2026 on October 28, 2026. The announcement will occur before market opening, followed by a webcast at 9:00 a.m. ET to discuss the results. A replay of the webcast will be accessible for one year on their investor relations website.
Read more →-LH
Sep 10, 2026Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
Labcorp hosted its 2026 Investor Day, reaffirming its guidance and outlining a long-term growth strategy through 2029. The company anticipates a compound annual revenue growth of 5% to 8% and adjusted earnings per share growth of 8.5% to 11.5%. Key strategic priorities include innovation in specialty testing and leveraging advanced technology to enhance healthcare delivery.
Read more →-LH
Sep 8, 2026Labcorp Acquires MLM Medical Labs, Expanding Global Central Laboratory and Biomarker Capabilities for Clinical Trials
Labcorp has acquired MLM Medical Labs, enhancing its global laboratory services and biomarker capabilities. This acquisition positions Labcorp as the only central laboratory provider with a wholly owned network across four continents. It aims to support complex clinical trials with improved scientific and operational oversight, particularly in emerging markets like Africa.
Read more →-LH
Aug 31, 2026Labcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial Complexity
Labcorp has launched enhancements to its Global Trial Connect platform, aimed at improving the clinical trial process for sponsors and investigator sites. The updates include a more intuitive user experience, streamlined study management tools, and enhanced visibility into study performance. These changes are designed to help users navigate the complexities of clinical trials more effectively.
Read more →-LH
Aug 28, 2026Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
Labcorp will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The executive management team will engage in a fireside chat, which will be available via a live audio webcast. This event highlights Labcorp's role in advancing healthcare through its laboratory services.
Read more →-LH
Aug 24, 2026Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings
Labcorp has announced the launch of the Elecsys® pTau-217 test, the first FDA-cleared blood test for detecting amyloid pathology associated with Alzheimer's disease. Targeted at individuals aged 55 and older with cognitive decline symptoms, this test offers a standardized assessment across various care settings. It aims to simplify the diagnostic process and improve access to timely evaluations for patients.
Read more →-LH
Aug 18, 2026Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health
Labcorp and the National Association of Community Health Centers (NACHC) have formed a strategic alliance to enhance leadership and improve health outcomes in Community Health Centers (CHCs) across the U.S. This collaboration includes the launch of the NACHC Leadership Exchange for Chief Medical Officers, aimed at developing clinical leaders. The partnership will leverage Labcorp's expertise in diagnostics and analytics to support healthcare delivery and practice improvement.
Read more →-LH
Aug 17, 2026Labcorp to Host Investor Day on September 10, 2026
Labcorp Holdings Inc. has announced an Investor Day scheduled for September 10, 2026. The event will feature presentations from key executives, including the CEO and CFO, discussing the company's strategic direction and financial outlook. A live webcast will be available, followed by a Q&A session.
Read more →-LH
Aug 10, 2026Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma
Labcorp has received FDA approval for its PGDx elio tissue complete CDx, a companion diagnostic that identifies advanced melanoma patients with specific BRAF variants. This approval enables clinicians to determine eligibility for targeted therapies, potentially improving treatment outcomes for patients with this aggressive cancer. The diagnostic is designed for use in hospitals and clinical labs, facilitating broader access to essential testing.
Read more →-LH
Aug 4, 2026Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer
Labcorp has launched the VENTANA PTEN (SP218) RxDx Assay, the first FDA-approved immunohistochemistry test for detecting PTEN protein loss in prostate cancer. This companion diagnostic aids in identifying patients eligible for treatment with AstraZeneca's TRUQAP (capivasertib) combined with abiraterone acetate and prednisone. The assay enhances personalized treatment decisions and supports precision oncology.
Read more →-LH
Jul 30, 2026Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance
Labcorp Holdings Inc. announced its second quarter results for 2026, showcasing a revenue increase of 5.8% to $3.73 billion and a 28.5% rise in diluted EPS to $3.64. The company raised its full-year guidance for revenue growth and adjusted EPS, reflecting strong operational momentum. Additionally, Labcorp expanded its oncology services and launched a new genetic health panel, enhancing its offerings in personalized health insights.
Read more →-LH
Jul 27, 2026Labcorp Launches Marker by Labcorp™ Genetic Health Panel, Expanding Consumer Access to Hereditary Genetic Risk Testing
Labcorp has launched the Marker by Labcorp™ Genetic Health Panel, which analyzes 163 genes linked to over 100 medically actionable conditions. This new offering, available through Labcorp OnDemand, includes genetic counseling to help consumers understand their results. The initiative aims to enhance consumer access to hereditary genetic risk testing and improve health insights.
Read more →About Labcorp Holdings Inc.
Headquarters358 S MAIN ST, BURLINGTON, NC, 27215
BIOPHARMAWATCH ELITE PLUS
Trade the next LH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime